As Philips stares down an international recall of more than 2 million of its CPAP and sleep apnea machines, the respiratory devicemaker ResMed is looking to pick up the slack—but the surge in demand from people looking to regain a healthy night’s sleep has greatly strained an already-crimped supply chain, compelling the company to ration its hardware.

ResMed CEO Mick Farrell said during the company’s quarterly earnings call that he expects to see the recalls drive $300 million to $350 million in additional sales over its 2022 fiscal year, which began July 1.

That’s despite production limitations brought on by a months-long global shortage of computer chips during the COVID-19 pandemic—affecting nearly every industry that relies on electronic components, from auto manufacturing to consumer products to solar power and even light bulbs.

Read the full article on Fierce Biotech.